Shots:
- The EC has approved Rhapsido (Remibrutinib) for the treatment of adults with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment
- Approval was supported by P-III (REMIX-1 & 2) trials (n=925) in CSU pts, where remibrutinib showed superior improvements in itch, hives & weekly urticaria activity at Wk.12 vs PBO in pts uncontrolled on H1-antihistamines, with a favorable safety profile requiring no lab monitoring
- Rhapsido (PO, BID) blocks BTK to inhibit the release of histamine & other proinflammatory mediators for CSU treatment, plus it is being evaluated across multiple trials for CIndU, hidradenitis suppurativa, & food allergy
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis’ Rhapsido (Remibrutinib) Receives the US FDA’s Approval for Chronic Spontaneous Urticaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
